Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to the UGT1A1 Genotype of Patients With Cancer

PURPOSE: The risk of severe neutropenia from treatment with irinotecan is related in part to UGT1A1*28, a variant that reduces the elimination of SN-38, the active metabolite of irinotecan. We aimed to identify the maximum-tolerated dose (MTD) and dose-limiting toxicity (DLT) of irinotecan in patien...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Innocenti, Federico, Schilsky, Richard L., Ramírez, Jacqueline, Janisch, Linda, Undevia, Samir, House, Larry K., Das, Soma, Wu, Kehua, Turcich, Michelle, Marsh, Robert, Karrison, Theodore, Maitland, Michael L., Salgia, Ravi, Ratain, Mark J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Clinical Oncology 2014
Aiheet:
ORIGINAL REPORTS
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4105486/
https://ncbi.nlm.nih.gov/pubmed/24958824
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.55.2307
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia